Cue Biopharma, Inc. (CUE) — insider trading
Health Care · NASDAQ
Cue Biopharma, Inc. (CUE) has 48 reported SEC Form 4 insider transactions in our data, including 2 open-market purchases and 15 open-market sales among the most recent 48 (latest 2026-10-12).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-10-12 | Meluzio Michael Vincent | Officer (VP, Prin. Accounting Officer) | Open-market sale | 1,144 | $28.05 | $32.1K | Form 4 |
| 2026-10-12 | Lin Shao-Lee | Director, Officer (Chief Executive Officer) | Open-market sale | 1,087 | $28.05 | $30.5K | Form 4 |
| 2026-10-12 | Lin Shao-Lee | Director, Officer (Chief Executive Officer) | Open-market sale | 10,000 | $27.50 | $275.0K | Form 4 |
| 2026-10-12 | Ray Sumita | Officer (Chief Legal Compliance Officer), Other | Open-market sale | 1,844 | $28.05 | $51.7K | Form 4 |
| 2026-08-13 | Meluzio Michael Vincent | Officer (VP, Prin. Accounting Officer) | Option exercise / conversion (derivative) | 13,647 | — | $0 | Form 4 |
| 2026-08-13 | Meluzio Michael Vincent | Officer (VP, Prin. Accounting Officer) | Open-market sale | 3 | $31.13 | $93 | Form 4 |
| 2026-08-13 | Meluzio Michael Vincent | Officer (VP, Prin. Accounting Officer) | Open-market sale | 4,106 | $30.35 | $124.6K | Form 4 |
| 2026-08-13 | Meluzio Michael Vincent | Officer (VP, Prin. Accounting Officer) | Open-market sale | 1,519 | $29.37 | $44.6K | Form 4 |
| 2026-08-13 | Meluzio Michael Vincent | Officer (VP, Prin. Accounting Officer) | Option exercise / conversion | 13,647 | — | $0 | Form 4 |
| 2026-08-13 | Ray Sumita | Officer (Chief Legal Compliance Officer), Other | Option exercise / conversion (derivative) | 18,196 | — | $0 | Form 4 |
| 2026-08-13 | Ray Sumita | Officer (Chief Legal Compliance Officer), Other | Open-market sale | 4 | $31.13 | $125 | Form 4 |
| 2026-08-13 | Ray Sumita | Officer (Chief Legal Compliance Officer), Other | Open-market sale | 6,442 | $30.35 | $195.5K | Form 4 |
| 2026-08-13 | Ray Sumita | Officer (Chief Legal Compliance Officer), Other | Open-market sale | 2,383 | $29.37 | $70.0K | Form 4 |
| 2026-08-13 | Ray Sumita | Officer (Chief Legal Compliance Officer), Other | Option exercise / conversion | 18,196 | — | $0 | Form 4 |
| 2026-08-13 | Lin Shao-Lee | Director, Officer (Chief Executive Officer) | Open-market sale | 10,460 | $29.48 | $308.4K | Form 4 |
| 2026-08-13 | Lin Shao-Lee | Director, Officer (Chief Executive Officer) | Open-market sale | 2,375 | $28.11 | $66.8K | Form 4 |
| 2026-08-13 | Lin Shao-Lee | Director, Officer (Chief Executive Officer) | Open-market sale | 5,423 | $27.19 | $147.5K | Form 4 |
| 2026-08-12 | Lin Shao-Lee | Director, Officer (Chief Executive Officer) | Option exercise / conversion (derivative) | 109,179 | — | $0 | Form 4 |
| 2026-08-12 | Lin Shao-Lee | Director, Officer (Chief Executive Officer) | Open-market sale | 5,775 | $27.75 | $160.3K | Form 4 |
| 2026-08-12 | Lin Shao-Lee | Director, Officer (Chief Executive Officer) | Open-market sale | 34,225 | $26.99 | $923.7K | Form 4 |
| 2026-08-12 | Lin Shao-Lee | Director, Officer (Chief Executive Officer) | Option exercise / conversion | 109,179 | — | $0 | Form 4 |
| 2026-07-30 | Ahlers James M | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 51,000 | — | $0 | Form 4 |
| 2026-07-30 | Ahlers James M | Officer (Chief Financial Officer) | Grant / award / vesting | 25,500 | — | $0 | Form 4 |
| 2026-07-13 | Borie Dominique Christian | Officer (Chief Medical Officer), Other | Grant / award / vesting (derivative) | 63,000 | — | $0 | Form 4 |
| 2026-07-13 | Borie Dominique Christian | Officer (Chief Medical Officer), Other | Grant / award / vesting | 31,500 | — | $0 | Form 4 |
| 2026-07-09 | Sarraf Pasha | Director | Grant / award / vesting | 18,400 | — | $0 | Form 4/A |
| 2026-07-09 | Garzone Pamela | Director | Grant / award / vesting | 18,900 | — | $0 | Form 4/A |
| 2026-07-09 | Lin Shao-Lee | Director, Officer (Chief Executive Officer) | Grant / award / vesting (derivative) | 327,537 | — | $0 | Form 4 |
| 2026-07-09 | Lin Shao-Lee | Director, Officer (Chief Executive Officer) | Grant / award / vesting | 327,537 | — | $0 | Form 4 |
| 2026-07-09 | Ray Sumita | Officer (Chief Legal Compliance Officer), Other | Grant / award / vesting (derivative) | 54,589 | — | $0 | Form 4 |
| 2026-07-09 | Ray Sumita | Officer (Chief Legal Compliance Officer), Other | Grant / award / vesting | 54,589 | — | $0 | Form 4 |
| 2026-07-09 | Meluzio Michael Vincent | Officer (VP, Prin. Accounting Officer) | Grant / award / vesting (derivative) | 40,942 | — | $0 | Form 4 |
| 2026-07-09 | Meluzio Michael Vincent | Officer (VP, Prin. Accounting Officer) | Grant / award / vesting | 40,942 | — | $0 | Form 4 |
| 2026-07-09 | Meehan Viola Mong | Director | Grant / award / vesting | 21,800 | — | $0 | Form 4 |
| 2026-07-09 | Sarraf Pasha | Director | Grant / award / vesting | 21,800 | — | $0 | Form 4 |
| 2026-07-09 | Camardo Daniel A. | Director | Grant / award / vesting | 21,800 | — | $0 | Form 4 |
| 2026-07-09 | Garzone Pamela | Director | Grant / award / vesting | 21,800 | — | $0 | Form 4 |
| 2026-06-01 | Lin Shao-Lee | Director, Officer (Chief Executive Officer) | Grant / award / vesting (derivative) | 45,453 | — | — | Form 4/A |
| 2026-06-01 | Lin Shao-Lee | Director, Officer (Chief Executive Officer) | Grant / award / vesting (derivative) | 90,906 | $11.00 | $1000.0K | Form 4/A |
| 2026-06-01 | Lin Shao-Lee | Director, Officer (Chief Executive Officer) | Open-market purchase (derivative) | 45,453 | — | — | Form 4 |
| 2026-06-01 | Lin Shao-Lee | Director, Officer (Chief Executive Officer) | Open-market purchase (derivative) | 90,906 | $11.00 | $1000.0K | Form 4 |
| 2026-05-30 | Camardo Daniel A. | Director | Grant / award / vesting (derivative) | 1,626 | — | $0 | Form 4 |
| 2026-05-30 | Meehan Viola Mong | Director | Grant / award / vesting (derivative) | 1,626 | — | $0 | Form 4 |
| 2026-05-03 | Lin Shao-Lee | Director, Officer (CHIEF EXECUTIVE OFFICER) | Grant / award / vesting (derivative) | 655,074 | — | $0 | Form 4 |
| 2026-05-03 | Lin Shao-Lee | Director, Officer (CHIEF EXECUTIVE OFFICER) | Grant / award / vesting | 327,537 | — | $0 | Form 4 |
| 2026-04-09 | Baker Daniel G. | Officer (CHIEF DEVELOPMENT OFFICER) | Grant / award / vesting (derivative) | 100,000 | — | $0 | Form 4 |
| 2026-04-09 | Warren Lucinda | Officer (CHIEF BUSINESS OFFICER) | Grant / award / vesting (derivative) | 250,000 | — | $0 | Form 4 |
| 2026-04-09 | Sandercock Colin | Officer (SVP, GENERAL COUNSEL) | Grant / award / vesting (derivative) | 200,000 | — | $0 | Form 4 |
Ask the chat about CUE's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: Cue Biopharma, Inc. (CUE).
Last updated 2026-10-12 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.